Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?

Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Revive Therapeutics

Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...

Two Binary Events Directly Ahead. As in Months Away, not Years. Share Price up 76% During April.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...

New Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story...

New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE

Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs

Ehave’s Mobile Ketamine Clinic, Rolling into Town.

Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...

The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...
Psychedelic Stock Review

Coming This Monday..

Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November...

Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Not wanting to be caught...

Latest article

Smart for Life (SMFL) Capitulates?

We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....

Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%

Nearly 100 Alzheimer’s programs have failed in the past decade. Biotech investors should study or at least become...

Novogratz Remains Steadfast on Crypto, Says Wait Until Next Year (Bloomberg)

Great call. This was actually from Late 2018. (Bloomberg) — Billionaire investor Michael Novogratz is resolute when it...